

FUTURE READY



TB Vaccines Dialogue Synthesis Report

→ | A. Executive Summary

A high-level, interactive TB Vaccines Dialogue was co-organized by the Ministry of Health of the Republic of Indonesia and the Stop TB Partnership to convene a diverse group of stakeholders and partners, including civil society and communities, for a concrete, practical, and action-oriented conversation around the future development and delivery of TB vaccines.

The key takeaways from the TB Vaccines Dialogue underscored the critical importance of:

Increased funding

- Current levels of investment in TB vaccine research and development are inadequate, particularly compared to other infectious diseases.

Accelerated action

- While the global community is working towards having a new TB vaccine by 2028, there are concerns about the slow pace of progress, especially given the huge impact a TB vaccine may have on reducing morbidity and mortality globally.
- Countries need to get ready now to roll-out TB vaccines as soon as they are available.

Equitable access

- It is critical to ensure that a new TB vaccine is both affordable and accessible to those that need it the most, particularly in low- and middle-income settings. There's a need to address TB-related stigma and vaccine hesitancy, and build strong health systems to deliver the vaccine.

Collaboration and coordination

- Greater coherence and coordinated efforts among governments, international organizations, civil society, and the private sector will maximize the impact of future TB vaccines.

“Let's stop talking and let's start doing and save the 4000 people a day that die from tuberculosis.”

Hon. Minister Budi Gunadi Sadikin,
Minister of Health, Republic of
Indonesia



Participants highlighted the need to learn from recent delivery experiences of other vaccines, such as COVID-19 and malaria vaccine introductions, to help with the effective planning and preparations for the delivery of TB vaccines as soon as they are available.

They also emphasised that the global TB community will need to continue to support efforts, now and in the future, to address TB at the country-level beyond TB vaccination.

A number of areas where the Stop TB Partnership could play a critical, collaborative role in planning and preparing for the future development and delivery of TB vaccines include:

- Advocating for increased political will and funding;
- Strengthening the coordination among a diverse group of stakeholders and partners, particularly civil society and communities, to ensure a more end-to-end and inclusive approach to the development and delivery of TB vaccines;
- Supporting countries to plan and prepare for the concrete and practical delivery of future TB vaccines by strengthening health systems and developing community engagement strategies, particularly in low- and middle-income countries;
- Working with civil society and communities to develop and implement targeted awareness and education campaigns to reduce TB-related stigma and promote the importance of TB vaccination; and
- Monitoring the progress on the development and delivery of TB vaccines and providing regular, real-times updates to stakeholders and partners.

→ | B. Introduction

The Ministry of Health of the Republic of Indonesia and the Stop TB Partnership co-organized a high-level, interactive TB Vaccines Dialogue on Tuesday, 24 September 2024 in New York City during the United Nations General Assembly (UNGA) and in advance of the second UN High-Level Meeting on Antimicrobial Resistance (UNHLM on AMR).

68 stakeholders and partners from 39 organisations, including ministries of health, non-governmental organizations, civil society and communities, donors and funders, multilateral and technical agencies, and the private sector participated in the meeting.

In order to ensure a concrete, practical, and action-oriented conversation, the TB Vaccines Dialogue was designed around a “Fishbowl Exchange” to encourage participants to have an unscripted, open discussion around the pre-identified key questions and critical challenges through an anonymous Insights Survey related to the development and delivery of TB vaccines.

The final **Agenda** and **Participants List** can be found in Annex B.

“We did not get it right in COVID, but we have to get it right this time.”

→ | C. Background

As a follow-up to the TB vaccines session at the Stop TB Partnership’s [37th Board Meeting](#) in February 2024 in Brasilia, Brazil and in alignment with the Board’s approval of the Secretariat’s efforts to convene a diverse group of stakeholders and partners, including civil society and communities, to further increase the momentum on the development and delivery of future TB vaccines, the TB Vaccines Dialogue was organized to have a more concrete, practical, and action-oriented conversation, as well as identify the next steps.

To achieve this objective and ensure a people-centered approach, the design of the TB Vaccines Dialogue drew on the learnings from an anonymous Insights Survey to better understand the participant’s key questions and critical challenges. This survey was completed by 61 participants ahead of the meeting and the initial analysis of the results was carried out by a generative AI solution, with the findings helping to structure the agenda.

→ | D. Insights Survey

The anonymous Insights Survey asked four general questions.

1. What are the two things you would like to better know and understand about TB vaccines?
2. What do you think will be the two main challenges in having a TB vaccine ready by 2028?
3. What do you think will be the two main challenges in getting people vaccinated with a TB vaccine?
4. How can the Stop TB Partnership help, considering our mandate and strengths, in having a TB vaccine ready by 2028 and getting people vaccinated with a TB vaccine?

Based on the initial analysis of the results, two key questions and critical challenges identified by participants were related to funding and financial resources and awareness and education.

The **Insights Survey Analysis Presentation** can be found in Annex C.

“The vaccine is not a magic bullet alone. We need to be supported to continue to fight the disease at the community level while the efforts are also going on at the top to make sure that we get an effective vaccine.”

→ | E. Key Themes

The conversation focused on the urgent need for new TB vaccines, highlighting the challenges and opportunities in research and development, financing, and delivery. Several themes emerged from the discussion:

- **Funding:** The lack of sufficient funding for TB vaccines emerged as a major concern, with participants advocating for increased investments, particularly to support the clinical trials and to ensure equitable access. In response, the TB Vaccine Accelerator council plans to hold the first global conference on the financing of TB vaccines and access in 2025. There were also

“Of all the work we do, the hardest to mobilize resources and support for is tuberculosis, even though it's the leading single cause of death due to infectious disease.”

specific concerns raised about how non-Gavi countries would access TB vaccines in the future, and suggestions that all governments should consider how to raise the necessary domestic resources to implement the future TB vaccination programmes.

- **Vaccine pipeline:** While the vaccine pipeline has vastly improved, it is still considered inadequate, and efforts should be made to improve the currently limited pipeline. The challenges of funding and conducting clinical trials for new TB vaccines were discussed. For example, the development and evaluation of TB vaccines is hindered by the absence of correlates of protection, which are measurable signs in the body (e.g. levels of antibodies), that indicate a person is protected from infection or disease. In TB vaccine trials, the lack of correlates requires larger, longer, and more expensive studies to track disease outcomes in populations over time.
- **Manufacturing and supply chain:** The need to establish robust manufacturing capacity and supply chains at the scale needed for the new TB vaccines was highlighted, with a focus on ensuring timely and equitable distribution.
- **Equitable access:** Participants stressed the importance of ensuring equitable access to new TB vaccines, particularly in low- and middle-income countries. There have been recent efforts to increase equitable access to vaccines in general, such as the launch of the Africa Vaccine Manufacturers Initiative. The discussion emphasised that the rollout of future TB vaccines should build on these efforts. It is also critical to consider how vaccine programmes can reach the most disadvantaged populations, and the polio programme may provide important lessons. Furthermore, concerns were raised about how the non-Gavi countries would access and afford the future TB vaccines.

“One of the key priorities... is to support equitable and affordable access to vaccines and this is of paramount importance. The TB vaccine is one of our priority vaccines.”

- **Country readiness:** Participants highlighted the need for strong health systems and community engagement to support effective delivery. Countries will need to be ready to roll out the future TB vaccines as soon as they are available to maximise the impact and will need to begin preparations in advance. This will be challenging as participants recognised that vaccination programmes are becoming increasingly complex given the inclusion of new vaccines in national schedules and the provision of vaccines along the life-course. The target population of adolescents will be relatively new for many countries and strategies to mobilise and reach them will need to be developed.

- **Learning from experience:** The global community should build on the learnings from recent vaccine introductions, including the malaria and COVID-19 vaccine rollouts on topics such as vaccine equity and demand forecasting.

“COVID has shown that even once a vaccine is available, actually bringing it to the people brings totally different challenges. I've also seen this recently with the malaria vaccine.”

- **Awareness and education:** The need to address TB-related stigma and build public awareness around TB vaccination was emphasized, particularly in populations that have historically been underserved by health systems. There will also need to be strategies put in place to address vaccine hesitancy and the anti-vaccine movements.
- **Coordination and collaboration:** The importance of a coordinated effort among all stakeholders (across TB and vaccines programmes), including governments, international organizations, civil society, and the private sector, was emphasized, with a call for greater coherence and collaboration to maximize impact.

“We need to foster global collaboration among governments, public and private institutions, and donors, and ensure that the vaccines are not only developed, but also made available to people equitably, learning from the painful lessons of access to COVID vaccines.”

Hon. Anupriya Patel, Union Minister of State, Ministry of Health and Family Welfare of India



→ | F. Next Steps

The Insights Survey and the TB Vaccines Dialogue discussion identified several potential areas where the Stop TB Partnership could provide added value and help related to the concrete and practical development and delivery of TB vaccines. Most importantly, it will be critical that the activities be aligned with the organization's [2023-28 Operational Strategy](#) and in collaboration with other stakeholders and partners, including the World Health Organization's [TB Vaccine Accelerator](#).

Some potential areas include:

1. Advocating for new, pooled resources for TB vaccine development, particularly candidates undergoing Phase 3 clinical trials;
2. Creating an enabling environment and building early demand in potential early adopter countries, and
3. Real-time knowledge sharing and country-to-country collaboration related to TB vaccine development and delivery.

The Stop TB Partnership will provide a comprehensive update about the next steps during the TB Vaccines Session at its [38th Board Meeting](#) from 12-14 December 2024 in Abuja, Nigeria.

ANNEX A

Final Agenda

TIME	SESSION	SPEAKERS
8:00-8:30 AM (30 mins.)	REGISTRATION NETWORKING BREAKFAST	
8:30-8:35 AM (5 mins.)	IS THIS JUST ANOTHER MEETING?	Dr. Lucica Ditiu (Executive Director, Stop TB Partnership)
8:35-8:45 AM (5 mins. / speaker)	LET'S BE INSPIRED!	Hon. Minister Budi Gunadi Sadikin (Minister of Health, Ministry of Health, Republic of Indonesia) Hon. Anupriya Patel (Union Minister of State, Ministry of Health and Family Welfare of India)
8:45-8:55 AM (10 mins.)	WHAT KEEPS YOU UP AT NIGHT? (Presentation of Insight Survey synthesis and thematic areas)	
8:55-9:55 AM (60 mins.)	FISHBOWL EXCHANGE... (Provocative, concrete, action- oriented conversation with core participants based on Insights Survey synthesis and thematic areas)	
9:55-10:00 AM (5 mins.)	READY. SET. GO.	Dr. Lucica Ditiu (Executive Director, Stop TB Partnership)

ANNEX B

Final Participants List

(FB=Fishbowl Exchange Participants)
(IP=In-person | V=Virtual)

<p>Anamaria Bejar IP</p> <p>Director, Public Policy Engagement Gavi, The Vaccine Alliance Switzerland</p>	<p>Andrew Cross V</p> <p>Strategic Initiatives Manager Stop TB Partnership Switzerland</p>
<p>Anjali Nayyar IP</p> <p>Executive Vice President Global Health Strategies Republic of Indonesia</p>	<p>Ann Ginsberg V</p> <p>Deputy Director, Tuberculosis Gates Foundation United States of America</p>
<p>Hon. Anupriya Patel IP/FB</p> <p>Union Minister of State Ministry of Health and Family Welfare Government of India</p>	<p>Ariane McCabe IP</p> <p>Senior Director, Global Health Policy and Advocacy Lead GSK Plc Switzerland</p>
<p>Ashling Mulvaney V</p> <p>Senior Programme Officer Gates Foundation United Kingdom</p>	<p>Austin Arinze Obiefuna IP/FB</p> <p>Executive Director, Afro Global Alliance Vice-Chair, Stop TB Partnership Board Ghana</p>
<p>Birgitte Giersling V</p> <p>Team Lead, Vaccine Prioritization and Platforms Immunization, Vaccines and Biologicals Department World Health Organization</p>	<p>Bonanza Taihitu IP</p> <p>Ministry of Health Republic of Indonesia</p>

<p>Bruce Aylward</p> <p>Assistant Director General, Universal Health Coverage, Life Course World Health Organization Switzerland</p>	<p>IP/FB</p>	<p>Hon. Budi Gunadi Sadikin</p> <p>Minister of Health Ministry of Health Republic of Indonesia</p>	<p>IP/FB</p>
<p>Chanthorn Phorng</p> <p>Manager, Policy, Advocacy, and Resource Mobilization Khmer HIV/AIDS NGO Alliance (KHANA) Kingdom of Cambodia</p>	<p>IP</p>	<p>Choub Sok Chamreun</p> <p>Executive Director Khmer HIV/AIDS NGO Alliance (KHANA) Kingdom of Cambodia</p>	<p>IP/FB</p>
<p>Colin Puzo Smith</p> <p>Global Policy Director RESULTS United States of America</p>	<p>IP</p>	<p>Deliana Garcia</p> <p>Chief Program Officer, International and Emerging Issues Migrant Clinicians Network United States of America</p>	<p>IP/FB</p>
<p>Diah Handayani</p> <p>Clinical Senior Lecturer Faculty of Medicine Universitas Indonesia / Persahabatan Hospital Republic of Indonesia</p>	<p>IP</p>	<p>Elise Rodriguez</p> <p>Head of Advocacy, European Union & France Global Health Advocates France</p>	<p>IP</p>
<p>Emily Bancroft</p> <p>Chief Executive Officer and President VillageReach United States of America</p>	<p>IP/FB</p>	<p>Emily Wootton</p> <p>Consultant Stop TB Partnership Switzerland</p>	<p>V</p>
<p>Erlina Burhan</p> <p>Professor of Respiratory Medicine Faculty of Medicine Universitas Indonesia / Persahabatan Hospital Republic of Indonesia</p>	<p>IP/FB</p>	<p>Felicitas Riedl</p> <p>Director of the Innovation and Competitiveness Department European Investment Bank Luxembourg</p>	<p>IP/FB</p>
<p>Fides Maria Aileen Buenafe</p> <p>Division Chief, Pharmaceutical Division Department of Health Republic of the Philippines</p>	<p>IP</p>	<p>Gillian Leitch</p> <p>Head of HIV, TB and Antimicrobial Resistance MedAccess United Kingdom</p>	<p>IP/FB</p>

<p>Han Nguyen V</p> <p>Senior Clinical Trial Manager Friends for International TB Relief Socialist Republic of Viet Nam</p>	<p>Hani Kim V</p> <p>Executive Director RIGHT Foundation Republic of Korea</p>
<p>Jacqueline Huh IP</p> <p>Head, External Affairs & Strategic Initiatives Stop TB Partnership Switzerland</p>	<p>Janet Ginnard IP/FB</p> <p>Director, Strategy Unitaid Switzerland</p>
<p>Jean-Bernard Parenteau IP/FB</p> <p>Director General, Global Health and Food Systems Bureau Global Affairs Canada Canada</p>	<p>Jerome Villacorta IP</p> <p>Department of Health Republic of the Philippines</p>
<p>Joanne Carter IP/FB</p> <p>Executive Director RESULTS / RESULTS Educational Fund United States of America</p>	<p>Kelly Collins IP/FB</p> <p>Vice President, Digital Adherence Dimagi United States of America</p>
<p>Kelsey Mertes IP</p> <p>Gates Foundation Senior Program Officer United States of America</p>	<p>L. Rizka Andalucia IP</p> <p>Ministry of Health Republic of Indonesia</p>
<p>Leander Grode IP/FB</p> <p>Managing Director Serum Life Science Europe GmbH Germany</p>	<p>Lucica Ditiu IP/FB</p> <p>Executive Director Stop TB Partnership Switzerland</p>
<p>Mario Ottiglio IP</p> <p>Managing Director, High Lantern Group Focal Point, Stop TB Partnership Board Private Sector Constituency Switzerland</p>	<p>Mark Feinberg IP/FB</p> <p>President and Chief Executive Officer International AID Vaccine Initiative (IAVI) United States of America</p>

<p>Megan Carroll IP</p> <p>Consultant Stop TB Partnership United States of America</p>	<p>Michelle Macaraig IP</p> <p>Executive Director, New York City Health Department Adjunct Professor, Rutgers University United States of America</p>
<p>Mike Frick IP/FB</p> <p>TB Project Co-Director Treatment Action Group United States of America</p>	<p>Monica Ruth Nirmala IP</p> <p>Ministry of Health Republic of Indonesia</p>
<p>Nandini Selvam IP/FB</p> <p>President IQVIA Government Solutions United States of America</p>	<p>Neni Nurainy IP</p> <p>Head, Translational Development of Life Science Products Bio Farma Indonesia</p>
<p>Nidhee Jadeja V</p> <p>Senior Manager, Policy Gavi, The Vaccine Alliance Switzerland</p>	<p>Nurul Nadia Luntungan IP</p> <p>President Stop TB Partnership Indonesia Republic of Indonesia</p>
<p>Olha Klymenko IP/FB</p> <p>Chairwoman of the Board TBPeopleUkraine Ukraine</p>	<p>Panayota Bird IP</p> <p>Senior Director MedAccess United Kingdom</p>
<p>Pascal Barollier IP/FB</p> <p>Chief of Public Engagement and Information Gavi, The Vaccine Alliance Switzerland</p>	<p>Patricia Waterous IP</p> <p>Director of Delivery Dimagi Canada</p>
<p>Paul Kelly IP/FB</p> <p>Chief Medical Officer Department of Health and Aged Care Government of Australia</p>	<p>Quennie Dyan Raagas IP</p> <p>Human Resource Management Officer V Health Human Resource Development Bureau - Career Development and Management Division Department of Health Republic of the Philippines</p>

<p>Raji Tajudeen</p> <p>Acting Deputy Director General Africa CDC Ethiopia</p>	<p>IP/FB</p>	<p>Ramphelane Morewane</p> <p>Acting Deputy Director-General of HIV/AIDS, TB, and Mother, Child, and Women’s Health National Department of Health Republic of South Africa</p>	<p>IP/FB</p>
<p>Richard White</p> <p>Professor, TB Vaccines London School of Hygiene and Tropical Medicine United Kingdom</p>	<p>V</p>	<p>Sarah Ewart</p> <p>Managing Partner Adduna Health Partners United States of America</p>	<p>V</p>
<p>Satyajit Sarkar</p> <p>Research Scientist International Vaccine Institute Republic of Korea</p>	<p>V</p>	<p>Selamawit Bekel</p> <p>Focal Point Stop TB Partnership Board Developed Country NGO Delegation United States of America</p>	<p>IP</p>
<p>Shaun Fernandes</p> <p>Associate Director CHAI United States of America</p>	<p>IP/FB</p>	<p>Shelly Malhotra</p> <p>Vice President, Global Access and External Affairs International AID Vaccine Initiative (IAVI) United States of America</p>	<p>IP</p>
<p>Sina Brückner</p> <p>Director, Clinical Operations Serum Life Science Europe GmbH Germany</p>	<p>IP</p>	<p>Stephen John</p> <p>Janna Health Foundation Nigeria</p>	<p>IP/FB</p>
<p>Suvanand Sahu</p> <p>Deputy Executive Director Stop TB Partnership Switzerland</p>	<p>IP</p>	<p>Taryn Russell</p> <p>Acting Executive Director RESULTS Canada Canada</p>	<p>IP</p>
<p>Tereza Kasaeva</p> <p>Director, Global TB Programme World Health Organization Switzerland</p>	<p>IP/FB</p>	<p>Thiago Luchesi</p> <p>Head, Public Policy and Analysis Gavi, The Vaccine Alliance Switzerland</p>	<p>IP</p>

Thomas Breuer	IP/FB	Timur Abdullaev	IP
Senior Vice President, Chief Global Health Officer GSK Plc Spain		Advisor to the Vice-Chair Stop TB Partnership Board	

ANNEX C

FUTURE READY : TB VACCINES DIALOGUE

Insight Survey Analysis

Background

- Based on your **key questions** and **critical challenges**
- Realistically and practically starts **answering** these key questions and **solving** these critical challenges
- **61** people responded to the Insights Survey
- Initial analysis done by a **generative AI solution**




Insights Survey Questions

Q1: What are the 2 things you would like to **better know and understand** about TB vaccines?

Q2: What do you think will be the 2 main challenges in **having a TB vaccine ready by 2028**?

Q3: What do you think will be the 2 main challenges in **getting people vaccinated** with a TB vaccine?

Q4: **How can STBP help**, considering our mandate and strengths, in having a TB vaccine ready by 2028 and in getting people vaccinated with a TB vaccine?



Q1: What are the 2 things you would like to better know and understand about TB vaccines?



1. Science and approval processes




2. Introduction and implementation planning



3. Economic and funding concerns



4. Country stakeholders and partners engagement – from policymakers to civil society / communities



Q2: What are the 2 main challenges in having a TB vaccine ready by 2028?



1. Funding and financial resources




2. Clinical trials and efficacy



3. Regulatory processes and approvals



4. Manufacturing and supply



Q3: What are the 2 main challenges in getting people vaccinated with a TB vaccines?



1. Awareness and education
 - Vaccine hesitancy / confidence / acceptance



2. Equity and access
 - Affordability and funding



3. Country-level policies



4. Integration with existing health systems / programmes



5. Global health organizations coordination



Fishbowl Exchange will focus on...



1. **Initial, unscripted reactions** to the Insights Survey's key themes (10 mins.)



2. **Funding and financial concerns** related to TB vaccines development (25 mins.)



3. **Awareness and education concerns** related to TB vaccines delivery (25 mins.)



FOR TODAY'S FISHBOWL EXCHANGE, WE WILL...

- Get your immediate reflections on the Insight Survey results – 10 mins.
- Focus on 1-2 key themes related to TB vaccines development – 20 mins.
- Focus on 1-2 key themes related to TB vaccines delivery – 20 mins.



→ **END
TB**

THANK YOU!